PulseSight Reports Phase I Data on Dry AMD Gene Therapy at EURETINA

PulseSight Therapeutics SAS, a Paris-based ophthalmology biotech, presented early efficacy data from its PST-611 Phase I clinical trial at the 26th EURETINA Congress in Vienna, the company announced Wednesday. The trial targets geographic atrophy, the advanced form of dry age-related macular degeneration, a leading cause of irreversible vision loss in older adults.

The data were delivered in an oral presentation at the European Society of Retina Specialists' annual congress, held October 1-4, 2026. The forum draws leading retinal specialists from across Europe and is considered a primary venue for emerging ophthalmic research.

Read more Capital Group Wins Abu Dhabi License in Middle East Push →

PST-611 is designed as a non-viral vectorized gene therapy administered through what the company describes as minimally invasive delivery technology. The non-viral approach distinguishes it from many competing gene therapy platforms, which typically rely on viral vectors and carry associated immunogenicity concerns.

Geographic atrophy affects millions of patients worldwide and has historically had limited treatment options. The Phase I trial represents an early but closely watched step for PulseSight as it seeks to validate both the safety profile and preliminary clinical signals of PST-611 in patients with advanced disease.

No detailed efficacy metrics or adverse-event data were disclosed in the company's announcement. Analysts and clinicians tracking the dry AMD treatment landscape are likely to await a full data readout before drawing broader conclusions about the therapy's competitive positioning. Continue reading at GlobeNewswire - Industry News on Financial Services.